Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS.NS)
INR 50.32
(4.77%)
INR 50.32
(4.77%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 3.95 Billion INR | -4.5% |
| 2022 | 4.14 Billion INR | -15.74% |
| 2021 | 4.91 Billion INR | 41.31% |
| 2020 | 3.47 Billion INR | 15.93% |
| 2019 | 3 Billion INR | -15.4% |
| 2018 | 3.54 Billion INR | 1.74% |
| 2017 | 3.48 Billion INR | -11.95% |
| 2016 | 3.95 Billion INR | 60.94% |
| 2015 | 2.46 Billion INR | 15.27% |
| 2014 | 2.13 Billion INR | 6.87% |
| 2013 | 1.99 Billion INR | 15.91% |
| 2012 | 1.72 Billion INR | 32.06% |
| 2011 | 1.3 Billion INR | 92.79% |
| 2010 | 676.8 Million INR | 45.54% |
| 2009 | 465.02 Million INR | 68.91% |
| 2008 | 275.31 Million INR | 9.9% |
| 2007 | 250.5 Million INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 1.26 Billion INR | -39.67% |
| 2023 FY | 3.95 Billion INR | -4.5% |
| 2023 Q1 | 509.56 Million INR | -67.79% |
| 2023 Q3 | 764.76 Million INR | 32.24% |
| 2023 Q2 | 578.31 Million INR | 13.49% |
| 2023 Q4 | 2.1 Billion INR | 175.06% |
| 2022 FY | 4.14 Billion INR | -15.74% |
| 2022 Q4 | 1.58 Billion INR | 153.21% |
| 2022 Q1 | 1.17 Billion INR | -1.54% |
| 2022 Q2 | 762.6 Million INR | -35.01% |
| 2022 Q3 | 624.71 Million INR | -18.08% |
| 2021 Q2 | 1.34 Billion INR | 38.08% |
| 2021 Q1 | 975.17 Million INR | -45.13% |
| 2021 Q3 | 1.4 Billion INR | 4.17% |
| 2021 Q4 | 1.19 Billion INR | -15.04% |
| 2021 FY | 4.91 Billion INR | 41.31% |
| 2020 FY | 3.47 Billion INR | 15.93% |
| 2020 Q1 | 252.17 Million INR | -77.22% |
| 2020 Q4 | 1.77 Billion INR | 123.14% |
| 2020 Q3 | 796.47 Million INR | 59.86% |
| 2020 Q2 | 498.24 Million INR | 97.58% |
| 2019 Q3 | 596.48 Million INR | -6.15% |
| 2019 Q4 | 1.1 Billion INR | 85.56% |
| 2019 Q1 | 662.03 Million INR | -51.77% |
| 2019 FY | 3 Billion INR | -15.4% |
| 2019 Q2 | 635.56 Million INR | -4.0% |
| 2018 Q2 | 716.36 Million INR | 6.35% |
| 2018 Q1 | 673.57 Million INR | -42.35% |
| 2018 Q3 | 784.36 Million INR | 9.49% |
| 2018 FY | 3.54 Billion INR | 1.74% |
| 2018 Q4 | 1.37 Billion INR | 75.02% |
| 2017 FY | 3.48 Billion INR | -11.95% |
| 2017 Q4 | 1.16 Billion INR | 30.46% |
| 2017 Q3 | 895.58 Million INR | 29.48% |
| 2017 Q2 | 691.69 Million INR | -6.25% |
| 2017 Q1 | 737.78 Million INR | -39.99% |
| 2016 Q2 | 824.04 Million INR | -12.9% |
| 2016 Q3 | 960.13 Million INR | 16.52% |
| 2016 FY | 3.95 Billion INR | 60.94% |
| 2016 Q4 | 1.22 Billion INR | 28.04% |
| 2016 Q1 | 946.11 Million INR | -12.91% |
| 2015 Q4 | 1.08 Billion INR | 71.54% |
| 2015 FY | 2.46 Billion INR | 15.27% |
| 2015 Q3 | 633.3 Million INR | 96.6% |
| 2015 Q2 | 322.13 Million INR | -23.03% |
| 2015 Q1 | 418.49 Million INR | -45.78% |
| 2014 Q4 | 771.9 Million INR | 46.29% |
| 2014 FY | 2.13 Billion INR | 6.87% |
| 2014 Q1 | 346.07 Million INR | -6.44% |
| 2014 Q2 | 488.77 Million INR | 41.23% |
| 2014 Q3 | 527.66 Million INR | 7.96% |
| 2013 Q4 | 369.89 Million INR | -36.6% |
| 2013 FY | 1.99 Billion INR | 15.91% |
| 2013 Q1 | 469.58 Million INR | -4.32% |
| 2013 Q2 | 574.39 Million INR | 22.32% |
| 2013 Q3 | 583.38 Million INR | 1.57% |
| 2012 Q3 | 482.47 Million INR | 19.36% |
| 2012 Q1 | 345.58 Million INR | -10.66% |
| 2012 FY | 1.72 Billion INR | 32.06% |
| 2012 Q2 | 404.22 Million INR | 16.97% |
| 2012 Q4 | 490.78 Million INR | 1.72% |
| 2011 Q3 | 323.54 Million INR | 0.0% |
| 2011 Q4 | 386.81 Million INR | 19.55% |
| 2011 FY | 1.3 Billion INR | 92.79% |
| 2010 FY | 676.8 Million INR | 45.54% |
| 2009 FY | 465.02 Million INR | 68.91% |
| 2008 Q4 | 62.8 Million INR | 0.0% |
| 2008 FY | 275.31 Million INR | 9.9% |
| 2007 FY | 250.5 Million INR | 0.0% |
| 2007 Q4 | 89.18 Million INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 61.12 Billion INR | 93.527% |
| Hester Biosciences Limited | 3.04 Billion INR | -29.904% |
| Aarti Drugs Limited | 25.28 Billion INR | 84.354% |
| Aarti Pharmalabs Limited | 18.15 Billion INR | 78.209% |
| Albert David Limited | 3.62 Billion INR | -9.148% |
| Alembic Limited | 1.57 Billion INR | -151.209% |
| Alkem Laboratories Limited | 126.67 Billion INR | 96.877% |
| Bafna Pharmaceuticals Limited | 1.52 Billion INR | -159.48% |
| Bajaj HealthCare Limited | 4.73 Billion INR | 16.434% |
| Biofil Chemicals and Pharmaceuticals Limited | 400.35 Million INR | -888.173% |
| Brooks Laboratories Limited | 794.86 Million INR | -397.72% |
| Eris Lifesciences Limited | 20.09 Billion INR | 80.309% |
| FDC Limited | 19.42 Billion INR | 79.638% |
| Glenmark Life Sciences Limited | 22.83 Billion INR | 82.673% |
| Gufic Biosciences Limited | 8.06 Billion INR | 50.956% |
| Hikal Limited | 17.84 Billion INR | 77.832% |
| Ind-Swift Limited | 5.02 Billion INR | 21.265% |
| Innova Captab Limited | 10.81 Billion INR | 63.413% |
| IOL Chemicals and Pharmaceuticals Limited | 21.32 Billion INR | 81.451% |
| Jagsonpal Pharmaceuticals Limited | 2.08 Billion INR | -89.561% |
| Jubilant Pharmova Limited | 67.02 Billion INR | 94.098% |
| Lincoln Pharmaceuticals Limited | 5.8 Billion INR | 31.855% |
| Lupin Limited | 196.56 Billion INR | 97.987% |
| Mangalam Drugs & Organics Limited | 3.67 Billion INR | -7.694% |
| Medico Remedies Limited | 1.44 Billion INR | -172.989% |
| Morepen Laboratories Limited | 17.01 Billion INR | 76.754% |
| Nectar Lifesciences Limited | 16.84 Billion INR | 76.515% |
| Orchid Pharma Limited | 8.19 Billion INR | 51.717% |
| Procter & Gamble Health Limited | 11.51 Billion INR | 65.636% |
| RPG Life Sciences Limited | 5.82 Billion INR | 32.03% |
| Kilitch Drugs (India) Limited | 1.54 Billion INR | -156.275% |
| Sigachi Industries Limited | 3.98 Billion INR | 0.837% |
| Solara Active Pharma Sciences Limited | 12.38 Billion INR | 68.054% |
| Suven Pharmaceuticals Limited | 10.51 Billion INR | 62.371% |
| Themis Medicare Limited | 3.81 Billion INR | -3.63% |
| Unichem Laboratories Limited | 16.57 Billion INR | 76.13% |
| Vaishali Pharma Limited | 862.79 Million INR | -358.53% |
| Wanbury Limited | 5.75 Billion INR | 31.275% |
| Windlas Biotech Limited | 6.3 Billion INR | 37.299% |
| ZIM Laboratories Limited | 3.67 Billion INR | -7.646% |
| Ind-Swift Laboratories Limited | 12.8 Billion INR | 69.114% |
| Ipca Laboratories Limited | 77.05 Billion INR | 94.866% |
| Sun Pharmaceutical Industries Limited | 484.96 Billion INR | 99.184% |
| Venus Remedies Limited | 5.91 Billion INR | 33.11% |
| Sakar Healthcare Limited | 1.54 Billion INR | -156.616% |
| Aurobindo Pharma Limited | 290.01 Billion INR | 98.636% |
| Divi's Laboratories Limited | 78.45 Billion INR | 94.957% |
| AstraZeneca Pharma India Limited | 12.95 Billion INR | 69.463% |
| Mankind Pharma Limited | 103.34 Billion INR | 96.172% |
| Sequent Scientific Limited | 13.69 Billion INR | 71.117% |
| Laurus Labs Limited | 50.01 Billion INR | 92.09% |
| Neuland Laboratories Limited | 15.58 Billion INR | 74.617% |
| J. B. Chemicals & Pharmaceuticals Limited | 34.47 Billion INR | 88.525% |
| Glenmark Pharmaceuticals Limited | 118.13 Billion INR | 96.651% |
| Zydus Lifesciences Limited | 190.21 Billion INR | 97.92% |
| Amrutanjan Health Care Limited | 4.21 Billion INR | 6.08% |
| Wockhardt Limited | 27.89 Billion INR | 85.815% |
| Bal Pharma Limited | 3.39 Billion INR | -16.626% |
| Dr. Reddy's Laboratories Limited | 279.16 Billion INR | 98.583% |
| Bliss GVS Pharma Limited | 7.7 Billion INR | 48.637% |
| Par Drugs and Chemicals Limited | 956.4 Million INR | -313.651% |
| Caplin Point Laboratories Limited | 16.76 Billion INR | 76.406% |
| Shilpa Medicare Limited | 11.53 Billion INR | 65.691% |
| Valiant Laboratories Limited | 1.82 Billion INR | -117.304% |
| Ajanta Pharma Limited | 42.08 Billion INR | 90.6% |
| Granules India Limited | 45.06 Billion INR | 91.221% |
| Medicamen Biotech Limited | 1.79 Billion INR | -120.638% |
| Syncom Formulations (India) Limited | 2.59 Billion INR | -52.604% |
| Piramal Enterprises Limited | 60.33 Billion INR | 93.443% |
| Torrent Pharmaceuticals Limited | 106.05 Billion INR | 96.27% |
| NATCO Pharma Limited | 40.02 Billion INR | 90.114% |
| Suven Life Sciences Limited | 116.92 Million INR | -3283.403% |
| Krebs Biochemicals & Industries Limited | 504.21 Million INR | -684.621% |
| Strides Pharma Science Limited | 40.51 Billion INR | 90.234% |
| Indoco Remedies Limited | 18.17 Billion INR | 78.23% |
| Alpa Laboratories Limited | 1.08 Billion INR | -263.823% |
| Lasa Supergenerics Limited | 1.04 Billion INR | -279.18% |
| Sun Pharma Advanced Research Company Limited | 755.45 Million INR | -423.683% |